NASDAQ:AMRI - Nasdaq - US0124231095
21.74
0 (0%)
The current stock price of AMRI is 21.74 null. In the past month the price increased by 0.23%. In the past year, price increased by 48.4%.
Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.
ALBANY MOLECULAR RESH INC
26 CORPORATE CIRCLE
ALBANY NY 12212
CEO: William S. Marth
Phone: 518-512-2000
The current stock price of AMRI is 21.74 null.
The exchange symbol of ALBANY MOLECULAR RESH INC is AMRI and it is listed on the Nasdaq exchange.
AMRI stock is listed on the Nasdaq exchange.
ALBANY MOLECULAR RESH INC (AMRI) has a market capitalization of 937.43M null. This makes AMRI a Small Cap stock.
ALBANY MOLECULAR RESH INC (AMRI) has a support level at 21.73 and a resistance level at 21.75. Check the full technical report for a detailed analysis of AMRI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AMRI does not pay a dividend.
ALBANY MOLECULAR RESH INC (AMRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
ChartMill assigns a technical rating of 8 / 10 to AMRI. When comparing the yearly performance of all stocks, AMRI is one of the better performing stocks in the market, outperforming 87.04% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to AMRI. AMRI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months AMRI reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -46.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -8.78% | ||
ROA | -4.81% | ||
ROE | -18.86% | ||
Debt/Equity | 0.62 |